# radiomics.bio > Insight-based decision making ## Posts - [radiomics.bio and AstraZeneca join forces to explore the potential for an AI model to predict interstitial lung disease related to cancer treatment](https://radiomics.bio/radiomics-bio-and-astrazeneca-join-forces-to-explore-the-potential-for-an-ai-model-to-predict-interstitial-lung-disease-related-to-cancer-treatment/): Interstitial Lung Disease (ILD)/pneumonitis is a known adverse event associated with cancer treatments including chemotherapy, targeted therapy, immune checkpoint inhibitors, antibody–drug conjugates and radiotherapy.1 It is a potentially fatal condition and can diminish the quality of life for people with cancer, lead to discontinuation of treatment and increase health care costs. On average, direct costs associated with ILD can add up to $32,834 per patient annually (ranging from $1,824 to $116,927).2 It is a relatively common adverse event; for example, between 15-40% of patients receiving concurrent chemoradiation therapy for non-small cell lung cancer (NSCLC) will experience symptomatic radiation pneumonitis.3   To address ... - [radiomics.bio Announces New Chairman](https://radiomics.bio/radiomics-bio-announces-new-chairman-2/): radiomics.bio Welcomes Jan Groen as Chairman Liège, Belgium, – 08:00 CET, 10 March 2025 – radiomics.bio (OncoRadiomics SA)., a leading AI-powered medical imaging clinical research organization (CRO) based in Belgium’s LégiaPark business center, has announced the appointment of Dr. Jan Groen as the new chairman of the board of directors succeeding Dr. Michel Baijot.  Having served as Board Chairman since 2018, Michel has contributed immeasurably to the growth of radiomics.bio and has successfully guided the company through multiple phases.radiomics.bio is delighted to announce that as of the General Assembly decision of the 28th of February, Dr. Jan Groen will take over as Board Chairman. This transition marks a ... - [From Images to Impact: Radiomics' Solutions to Challenges in Immunotherapy](https://radiomics.bio/from-images-to-impact-radiomics-solutions-to-challenges-in-immunotherapy-2/): Cancer immunotherapy, harnessing the body’s immune system to fight malignant cells, represents a groundbreaking shift in the oncology landscape and has marked a turning point in cancer treatment achieving remarkable results in patients. In recent years, immunotherapy has emerged as the therapeutic option of choice for several advanced cancers.  However, accurate assessment of treatment response in immunotherapy is crucial. Unlike traditional chemotherapy, immunotherapy may not exhibit immediate tumour shrinkage, rendering conventional response criteria inadequate. The integration of Radiomics and Artificial Intelligence (AI) has the potential to revolutionise the field of immunotherapy response assessment, offering a promising avenue to enhance cancer treatment ... - [Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients](https://radiomics.bio/pilot-project-at-the-jewish-general-hospital-aims-to-accelerate-access-to-new-and-highly-effective-treatments-for-cancer-patients/): A new grant will support digital health solutions to advance precision medicine in cancer care, translating into personalized treatment matching and optimized outcomes for thousands of patients. Montreal, September 5, 2023 – A pilot project led by the Jewish General Hospital proposes a new promising approach to cancer treatment known as data-based precision oncology to accelerate access to new and highly effective treatments for cancer patients. This innovative strategy involves tailoring cancer treatments based on intricate details unique to each patient’s tumor.   In the 1990s, the inception of precision oncology saw doctors identifying specific DNA mutations within tumors in an attempt ... - [Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy](https://radiomics.bio/from-images-to-impact-radiomics-solutions-to-challenges-in-immunotherapy/): DeuterOncology joins forces with Radiomics to develop a clinical tool to predict patient response to treatment. DeuterOncology obtains SPW grant funding Liège, Belgium, April 07, 2023 – DeuterOncology, a Liège-Based (BE) biotech company, is pleased to announce it has successfully been awarded the Win4Company grant by the Wallonie recherche SPW. The clinical-stage drug development company has been granted 478,000 EUR for establishing a partnership with a Liège-based biotech, Radiomics,  for the development and validatation of an AI-based imaging biomarker as a potential companion diagnostic for a novel best-in-class deuterated MET kinase inhibitor (DO-2) as an optimized personalized cancer therapy. The grant brings ... - [Radiomics' Event Package For IO Xchange](https://radiomics.bio/belgian-biotech-companies-deuteroncology-and-radiomics-combine-their-expertise-to-improve-cancer-therapy-2/): Radiomics’ digital event package for Immuno-Oncology Xchange 2022 Sign up to get access to our brochures, papers and more. Radiomics is commited to intergrating sustainability into all of its activities. In order to do so an online version of our information package was created to reduce our carbon footprint.  Please fill in your details below and get access to all of the elements of our information package such as our latest poster on the “Delta-radiomics to predict response and survival in solid tumors after immune checkpoint inhibitors therapy.” - [Early Detection with Imaging](https://radiomics.bio/early-detection-with-imaging/): Paving the way for better diagnosis, treatment and care in pulmonary fibrosis Three Lakes Foundation brings together academia, clinicians and industry to identify imaging insights for early detection of interstitial lung disease/pulmonary fibrosis (ILD/PF). Please fill in your details below and get access to all of the elements of our information package such as our latest poster on the “Delta-radiomics to predict response and survival in solid tumors after immune checkpoint inhibitors therapy.” NORTHBROOK, Ill., November 10, 2022 — Three Lakes Foundation has announced the expansion of B4PF, an initiative focused on at-risk individuals for ILD/PF, early diagnosis and therapeutic development ... - [Radiomics’ Remarkable Relocation](https://radiomics.bio/radiomics-remarkable-relocation/): After 4 years, Radiomics is moving to LégiaPark  Liege (BE), 10/14/2022 -On September 19th, Radiomics officially opened doors to their new office at LégiaPark to provide for their ever-growing team and clients with the support they need. In a brand new 800m2 space, Radiomics will continue to serve its clients, develop its internal R&D and provide a modern and pleasant work environment for its most important asset: its collaborators. Additionally, Radiomics will host young partner companies in its internal incubator and is already looking into applications. “The objective of LégiaPark is to provide Life Science companies with workspaces adapted to their needs, ... - [Radiomics' Events Package For ESMO](https://radiomics.bio/radiomics-events-package-for-esmo/): Radiomics has created a digital information package for ESMO Congress to reduce our carbon footprint. Sign up to get access to our information package including our brochures, papers and more. Radiomics is commited to intergrating sustainability into all of its activities. In order to do so, an online version of our information package was created to minimise our impact on the environment.  Please fill in your details below and get access to all of the elements of our information package such as our latest brochure on Leveraging Radiomics in Early Phase Clinical Development.  - [The clinical needs and regulatory requirements of an imaging-based companion diagnostic](https://radiomics.bio/the-clinical-needs-and-regulatory-requirements-of-an-imaging-based-companion-diagnostic/): Radiomics has produced a series of articles aimed at providing a complete overview of imaging companion diagnostics and their development pathway. Imaging-based companion-diagnostics have the potential to change the treatment landscape for oncology patients. Radiomics  has produced a series of articles aimed at providing a complete overview of imaging-based companion diagnostics and their development pathway. The third article of the series: “Tecnical considerations for an imaging-based companion diagnostic” has now been released and is available. Please fill in your details below and get access to read the full article directly.  - [Radiomics' Sustainability Policy](https://radiomics.bio/radiomics-sustainability-policy/): Sustainability is more than just “being green,” to us it means to create a positive impact on society and environment by contributing to maintaining and improving our environment and society for future generations. For this we have decided to assess what we are already doing in the area, identify new improvement opportunities and to elaborate an official Radiomics sustainability policy that became effective in February 2022. At Radiomics, we adhere to the UN Sustainable Development Goals[1] and we have structured our framework around Environmental, Social and Governance (ESG) pillars. We have put in place 3 teams to ensure we reach our ... - [Radiomics' Events Information Package For ASCO](https://radiomics.bio/radiomics-events-information-package-for-asco/): Radiomics has created a digital information package for the American Society of Clinical Oncology (ASCO) to reduce our carbon footprint. Sign up to get access to our information package including our brochures, papers and more. Radiomics is commited to intergrating sustainability into all of its activities. In order to do so, an online version of our information package was created to minimise our impact on the environment.  Please fill in your details below and get access to all of the elements of our information package such as our latest brochure on Leveraging Radiomics in Early Phase Clinical Development.  - [Radiomics is officially ISO 13485 certified](https://radiomics.bio/radiomics-is-officially-iso-13485-certified/): Radiomics is pleased to announce its Quality Management System has been certified to be fully compliant with EN ISO 13485:2016 Medical Devices – Quality Management Systems – Requirements for regulatory purposes) standard by the notified body IMQ. The ISO 13485:2016 standard is based on the ISO 9001 and specifies the requirements an organization needs to demonstrate for the design, development, production, storage, distribution, installation or servicing of a medical device. The standard ensures, through the implementation of a quality management system, that all medical devices are safe and meet the applicable regulatory compliance laws and customer needs. Steven Lauwers, Chief ... ## Pages - [Cookie Policy](https://radiomics.bio/cookie-policy/) - [Privacy Policy](https://radiomics.bio/privacy-policy/) - [ISO Certifications](https://radiomics.bio/iso-27001-certification/) - [Compliance](https://radiomics.bio/compliance/) - [Contact](https://radiomics.bio/contact/) - [All events](https://radiomics.bio/all-events/) - [All publications](https://radiomics.bio/all-publications/) - [All news](https://radiomics.bio/all-news/) - [News and publications](https://radiomics.bio/news-and-publications/) - [Careers](https://radiomics.bio/careers/) - [Ikonics](https://radiomics.bio/ikonics/) - [Our services](https://radiomics.bio/our-services/) - [Overview](https://radiomics.bio/overview/) - [Sustainability](https://radiomics.bio/sustainability/) - [About us](https://radiomics.bio/about-us/) - [Home](https://radiomics.bio/) [comment]: # (Generated by Hostinger Tools Plugin)